As we close the door to the past, the promise of tomorrow is yet to come.
FROM THE CHAIRMAN
The beauty of a new year is the blank slate it presents. We close the book on the previous year, hopefully wiser from lessons learned, and charge forward expectantly. After last year, such a gift is particularly appreciated.
On that note, Psychiatric TimesTM is poised to jump into 2021 with great excitement. John J. Miller, MD, our editor in chief, explores the psychiatric treatments in the pipeline. Some of these agents leverage innovative psychopharmacology, and all offer the hope of improved outcomes for patients.
We also welcome new Section Editors to Psychiatric TimesTM Sheldon H. Preskorn, MD, a long-time contributor, now joins us as the Psychopharmacology Section Editor. Dr Preskorn is a professor in the Department of Psychiatry and Behavioral Sciences at the University of Kansas School of Medicine in Wichita. Also familiar to readers, Rajesh Tampi, MD, MS, DFAPA, chairman of the Department of Psychiatry & Behavioral Sciences at Cleveland Clinic Akron General in Akron, and chief of the Section for Geriatric Psychiatry at Cleveland Clinic, is now serving as our Geriatric Psychiatry Section Editor. As part of our commitment to diversity, Advisory Board member Frank A. Clark, MD, is our new Diversity and Inclusion Section Editor. Dr Clark is a clinical assistant professor at the University of South Carolina School of Medicine Greenville, and the medical director and division chief for Adult Inpatient and Consult-Liaison Services for the Department of Psychiatry and Behavioral Medicine at Prisma Health. We also welcome Anita H. Clayton, MD, chair of psychiatry and neurobehavioral sciences and the David C. Wilson Professor of Psychiaty and Neurobehavioral Sciences at the University of Virgina School of Medicine, as our Women’s Issues Section Edior. Horacio A. Capote, MD, medical director of the Division of Neuropsychiatry at Dent Neurologic Institute and medical director of addiction services at BryLin Hospital, in Buffalo, New York, will serve as our Neuropsychiatry Section Editor. In our continued effort to address collaboration, we are pleased to have Sara Robinson, MSN, RN, PMHNP-BC, join Psychiatric TimesTM as Nurse Practitioner Liaison. Ms Robinson is a psychiatric-mental health nurse practitioner in Portsmouth, New Hampshire, and a clinical assistant professor in the Department of Nursing at the University of New Hampshire College of Health and Human Services in Durham.
This year we are excited to highlight contributions from our partner organizations and associations. In this issue, David “Daven” E. Morrison, MD, and colleagues from the Committee on Work & Organizations of the Group for the Advancement of Psychiatry share their thoughts on job loss. Previous Psychiatric TimesTM articles have elucidated the direct neuropsychiatric implications of coronavirus disease 2019 (COVID-19). In this piece, these authors discuss how COVID-19 affects employment and how psychiatrists can assist their patients who are struggling with job loss.
There is much reason for optimism as we step into 2021: potential new treatments, a COVID-19 vaccine, and renewed hope and enthusiasm. Through it all, Psychiatric TimesTM is committed to keeping you up-to-date with the latest information and providing you with the resources you need to help your patients. If you have suggestions or requests to better assist you and your colleagues, let us know by emailing PTEditor@MMHGroup.com. ❒
Mike Hennessy Sr
Chairman and Founder, MJH Life SciencesTM